Promising combo tackles aggressive lymphoma in large trial

This Phase 3 trial tested whether adding tucidinostat (an oral HDAC inhibitor) to standard R-CHOP chemotherapy improves outcomes for people with newly diagnosed MYC/BCL2 double-expressor diffuse large B-cell lymphoma, an aggressive subtype. The study enrolled 423 adults who had not received prior treatment. Participants received either tucidinostat plus R-CHOP or a placebo plus R-CHOP for six cycles, with additional tucidinostat for those who achieved complete response. The main goal was to see if the combo extended event-free survival.